As the leading cause of dementia, Alzheimer's disease (AD) is a major burden on affected
individuals, their families and caregivers, and healthcare systems. Although AD can be …

The risk of Alzheimer disease (AD) increases with age, family history and informative genetic
variants. Sadly, there is still no cure or means of prevention. As in other complex diseases …

In the 115 years since the discovery of Alzheimer's disease (AD), our knowledge, diagnosis,
and therapeutics have significantly improved. Biomarkers are the primary tools for clinical …

Introduction β-synuclein (β-syn) is a presynaptic protein, whose cerebrospinal fluid (CSF)
levels are increased in patients with Alzheimer's diseases (AD) showing mild cognitive …

Recently, a fully automated instrument for the detection of the Cerebrospinal Fluid (CSF)
biomarker for Alzheimer's disease (AD)(low concentration of Amyloid-beta 42 (Aβ42), high …

Background and Objectives To elaborate a new algorithm to establish a standardized
method to define cutoffs for CSF biomarkers of Alzheimer disease (AD) by validating the …

INTRODUCTION We described patients' and care partners' experiences with Alzheimer's
disease (AD) cerebrospinal fluid (CSF) biomarker testing and result disclosure in routine …

Cerebrospinal fluid (CSF) biomarkers are essential for the accurate diagnosis of Alzheimer's
disease (AD), yet their measurement levels vary widely across centers and regions, leaving …

Fluid biomarkers are currently measured in cerebrospinal fluid and blood for Alzheimer's
disease diagnosis and are promising targets for drug development and for patients' follow …

Objectives Alzheimer's disease (AD) is considered the most common cause of dementia in
older people. Recently, blood-based markers (BBM) Aβ1-42, Aβ1-40, and phospho Tau181 …